文献速递生殖医学

男性焦虑和抑郁对IVF结局的影响

The effects of male anxiety and depression on IVF outcomes.
PubMed 文献 · Hum Reprod · 2023-01-01

这项基于问卷的回顾性队列研究在单一大型医院附属生殖中心纳入222名接受IVF(伴或不伴ICSI)的男性伴侣,用HADS评估焦虑和抑郁。HADS-A≥8者最终总活动精子数低于HADS-A<8者,但两组每移植活产率无差异;抑郁组样本量小,临床结局相似。

要点

  • HADS-A≥8的男性在取卵日最终总活动精子数低于HADS-A<8者,校正β=-0.66(95%CI -1.22,-0.10)。
  • HADS-A≥8与<8组每移植活产率相似:43.2% vs 45.1%,校正相对风险0.90(95%CI 0.65,1.06)。
  • 无论是否使用抗抑郁药,报告焦虑和/或抑郁与未报告的男性伴侣IVF活产率相似。

核心结论

  • 有焦虑的男性在IVF期间最终总活动精子数较低,但活产率无差异。
  • 无论是否使用抗抑郁药,报告与未报告焦虑和/或抑郁的男性伴侣IVF活产率相似。

研究设计与样本

  • 基于问卷的回顾性队列研究,在单一大型医院附属生殖中心完成,纳入222名接受IVF伴或不伴ICSI的 respondent(应答者),研究时间为2018年9月6日至2022年12月27日。
  • 男性伴侣完成医院焦虑抑郁量表(HADS)问卷,按HADS-A≥8或<8、HADS-D≥8或<8分为两组,HADS-A或HADS-D评分≥8分别视为有焦虑或抑郁。

主要发现

  • 222名应答者中,22.5%有HADS-A≥8,6.5%有HADS-D≥8;平均年龄37.38±4.90岁。
  • HADS-A或HADS-D≥8的应答者抗抑郁药使用率更高(P<0.05);吸烟使用在HADS-A和HADS-D各组间相似(P>0.05)。
  • 校正男性BMI、抗抑郁药使用和吸烟后,HADS-A或HADS-D≥8者与≤8者相比,勃起功能障碍(校正相对风险=1.12,95%CI 0.60,2.06)和性欲低下(校正相对风险=1.70,95%CI 0.91,3.15)发生率相似。
  • HADS-A≥8者取卵日最终总活动精子数更低(11.8 vs 20.1,校正β=-0.66,95%CI -1.22,-0.10)。
  • HADS-A≥8与<8组每移植活产率相似(43.2% vs 45.1%,校正相对风险=0.90,95%CI 0.65,1.06);HADS-D≥8与<8组最终总活动精子数(18.7 vs 16.0)和每移植活产率(46.7% vs 45.4%)临床相似。

关键数值与推荐

  • HADS-A≥8定义为有焦虑,HADS-D≥8定义为有抑郁。
  • 主要结局为活产率,次要结局包括IVF时精液参数、周期结局、妊娠结局以及勃起功能障碍和性欲低下的患病率。

临床怎么用

  • 作者认为,重要的是评估夫妻双方的心理健康,并且不应因担心抗抑郁药或焦虑/抑郁对精子质量的潜在影响而拒绝治疗。

局限性

  • 基于问卷的设计。
  • IVF时缺乏精子形态学评估。
  • 由于样本量小,无法充分评估HADS-D≥8队列。
  • 以白种人为主的人口统计学特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What are the effects of male anxiety and depression on IVF outcomes? SUMMARY ANSWER: Men with anxiety had lower final total motile sperm counts (fTMSC) during IVF compared to men without anxiety; however, there were no differences in live birth rates (LBRs). WHAT IS KNOWN ALREADY: Studies have shown that male anxiety causes low sperm motility, worse sperm morphology, and increased DNA fragmentation, which are known to be influential factors on fertilization rates and embryo quality during IVF. However, data are lacking on whether there is a direct association between male anxiety and/or depression and IVF outcomes. STUDY DESIGN, SIZE, DURATION: This was a survey-based, retrospective cohort study completed at a single, large hospital-affiliated fertility center with 222 respondents who underwent IVF with or without ICSI. The study was conducted between 6 September 2018 and 27 December 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: Male partners of couples who underwent IVF or IVF/ICSI completed a Hospital Anxiety and Depression Scale (HADS) questionnaire. They were separated into two groups for both anxiety (HADS-A ≥ 8 or HADS-A < 8) and depression (HADS-D ≥ 8 or HADS-D < 8). Men with an elevated HADS-A or HADS-D score ≥8 were considered to have anxiety or depression, respectively. The primary outcome was LBR. Secondary outcomes included semen parameters at the time of IVF, cycle outcomes, pregnancy outcomes, and prevalence of erectile dysfunction and low libido. MAIN RESULTS AND THE ROLE OF CHANCE: There were a total of 222 respondents, of whom 22.5% had a HADS-A ≥ 8 and 6.5% had a HADS-D ≥ 8. The average age of respondents was 37.38 ± 4.90 years old. Antidepressant use was higher in the respondents with a HADS-A or HADS-D ≥ 8 (P < 0.05). Smoking use was similar between groups for both HADS-A and HADS-D (P > 0.05). When adjusted for male BMI, antidepressant use and smoking, men with a HADS-A or HADS-D ≥ 8 had similar rates of erectile dysfunction (adjusted relative risk (aRR) = 1.12 (95% CI 0.60, 2.06)) and low libido (aRR = 1.70 (95% CI 0.91, 3.15)) compared to those with a HADS-A or HADS-D ≤ 8. Men with a HADS-A ≥ 8 were more likely to have a lower fTMSC on the day of oocyte retrieval (11.8 ≥ 8 vs 20.1 < 8, adjusted ß = -0.66 (95% CI -1.22, -0.10)). However, the LBR per embryo transfer (ET) was similar between the HADS-A groups (43.2% ≥8 vs 45.1% <8, adjusted relative risk = 0.90 (95% CI 0.65, 1.06)). Although depression was uncommon in the entire cohort, the HADS-D groups were clinically similar for fTMSC (18.7 ≥ 8 vs 16.0 < 8) and LBR per ET (46.7% ≥8 vs 45.4% <8). LIMITATIONS, REASONS FOR CAUTION: Limitations of our study are the survey-based design, the lack of sperm morphology assessment at the time of IVF, our inability to fully assess the HADS-D ≥ 8 cohort due to the small sample size and the large Caucasian demographic. WIDER IMPLICATIONS OF THE FINDINGS: Couples undergoing IVF have an increased likelihood of suffering from anxiety and/or depression. There is currently a debate on whether or not men should be treated with antidepressants while attempting to conceive due to potential detrimental effects on sperm quality. Our study shows that, regardless of antidepressant use, couples with men who did or did not report anxiety and/or depression have similar LBRs when undergoing IVF. Therefore, it is important to assess both partners for mental health and to not withhold treatment due to a concern about a potential impact of antidepressants or anxiety/depression on sperm quality. STUDY FUNDING/COMPETING INTEREST(S): There was no funding to report for this study. Z.W. is a contributing author for UptoDate. S.S.S. is on the advisory board for Ferring Pharmaceuticals. E.G. was a medical consultant for Hall-Matson Esq, Teladoc, and CRICO and is a contributing author for UptoDate. The remaining authors have nothing to report. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Walker Z, Ernandez J, Lanes A, et al. The effects of male anxiety and depression on IVF outcomes. Hum Reprod. 2023. PMID: 37690112. doi:10.1093/humrep/dead179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。